BioWorld

May 18, 2010

Astellas Acquires OSI for $4B; Sweetened Bid Melts Hostility

After an unsuccessful $3.5 billion hostile takeover attempt, Astellas Pharma Inc. raised its acquisition offer for OSI Pharmaceuticals Inc. to $4 billion, and OSI agreed to a friendly buyout. (BioWorld Today) Read More

ARCA Shares Get a Bounce on SPA OK for Beta-Blocker

Roxro Dodges Opioid, NSAID Traps; 'Smooth' Nod for Sprix

NewCo News: ElexoPharm's First License Deal Worth up to $41.6M from Merck

NuPathe Files for $86M IPO Ahead of Migraine Patch NDA

Clinic Roundup

Stock Movers

Other News To Note

ATS Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 11, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

Wuxi Apptec insists it’s ‘not a Chinese military company’

BioWorld

Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military...

Researchers hit back after colleagues removed from ADA meeting

BioWorld

Former principal officers of the American Diabetes Association (ADA) have hit back at the association’s board and CEO after it prohibited the distribution of an...